35 results about "Complement inhibition" patented technology

In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma.

The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.

The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.

The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.

We describe a method of detecting a therapeutic exosome, the method comprising detecting an activity of an exosome. The activity may be selected from the group consisting of: (a) immunodulatory activity; (b) complement inhibition activity; (c) proteasome activity; (d) glycolytic enzyme activity; (e) anti-oxidative activity; (f) extracellular matrix (ECM) modifying activity; (g) NT5E (CD73) ecto-5'-ectonucleotidase activity; (h) ion homeostasis activity; and (i) chaperone activity. If the exosome is detected as having one or more such activities, the exosome is likely to comprise a therapeutic exosome having therapeutic activity.

In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic respiratory system disorder. In some aspects, the invention provides methods of administering a complement inhibitor to a subject. In some embodiments, a method of treating a subject comprises administering multiple doses of a complement inhibitor to the subject according to a dosing schedule that leverages the prolonged effect of complement inhibition in chronic respiratory disorders. In some embodiments, a subject has chronic obstructive pulmonary disease. In some embodiments, a subject has asthma.

Factor H-binding peptides that binds to a region of factor H that does not impede the complement-inhibitory activity of factor H are disclosed. When immobilized onto the surface of a biomaterial, these peptides recruit factor H, resulting in a substantial inhibition of biomaterial-induced complement activation in a biological substance exposed to the biomaterial.

The present invention describes compositions and methods for targeting complement inhibition to sites of p-selectin expression, and compositions for inhibiting p-selectin and complement.

The invention discloses a fusion protein scFV-CD55 of an acetylcholine receptor-resistant single-chain antibody targeted complement regulatory factor CD55. The CD55 is targeted to neuromuscular transmission through single-chain antibody to inhibit combination of the antibody of a pathogenic acetylcholine receptor and the pathogenic acetylcholine receptor, block the cascade of a complement, protect the acetylcholine receptor and eliminate immune injury caused by complement system activation, so that myasthenia gravis is treated in a targeted way. The scFv-CD55 is obtained by coupling acetylcholine receptor-resistant single-chain antibody to the amino terminal of the complement regulatory factor CD55(SCR1-4) through (G4S1)3 connecting peptide. By means of genetic engineering, soluble scFV-CD55 can be obtained through prokaryotic expression and purification. Experiments prove that: the fusion protein scFV-CD55 maintains the affinity of the acetylcholine receptor and the complement inhibition function of the CD55, the complement inhibition function of the scFV-CD55 is obviously improved in cellular experiments, and the complement deposition on immune injury parts is reduced. The invention develops a new biological agent for treating the myasthenia gravis, and the biological agent has wide application prospect.

The invention discloses an anti-P-selectin single-chain antibody targeted complement inhibitor ScFv-CD59 and application thereof. The invention aims to provide an anti-P-selectin single-chain antibody targeted complement inhibitor ScFv-CD59 with specific targeting and the application thereof in preparing medicaments for treating systemic inflammations. The anti-P-selectin single-chain antibody targeted complement inhibitor ScFv-CD59 is a fusion protein obtained by connecting the amino terminal of the anti-P-selectin single-chain antibody ScFv with the complement inhibitor CD59 by using a connecting peptide. The experiment proves that the ScFv-CD59 can obviously improve the efficiency of inhibiting the complement-mediated cell cracking, can achieve high-degree accumulation at the immune injury part, can obviously inhibit the occurrence and degeneration of inflammations and can obviously reduce the side effect of infection caused by the complement inhibitor. Therefore, the ScFv-CD59 can be used as an active ingredient to be prepared into a novel gene engineering targeted protein medicament with a targeted P-selectin complement inhibitor for treating inflammations. The invention plays an important role in the pharmaceutical field and has wide application prospects.

The invention discloses the application of Bupleurum polysaccharide in the preparation of medicine for treating myocardial injury. During myocardial injury, ROS / P53 / S100‑A9 can form a subtle positive feedback pathway, which acts with C3 during myocardial injury, activates the expression of downstream complement proteins, and activates the complement system to aggravate myocardial injury. The innovation point of the present invention is to start from the above mechanism, apply the complement inhibitory active Bupleurum polysaccharide to the treatment of myocardial injury, and reduce the myocardial injury by inhibiting the complement system activated by the positive feedback pathway. This provides a new treatment method for myocardial injury clinically.

The invention discloses a fusion protein of a complement receptor 2 variant and a complement inhibitor fH and an application of the fusion protein in the preparation of a drug for treating autoimmune diseases. The complement receptor 2 variant is a molecular modification obtained after computer modeling and amino acid substitution, and has higher ligand binding and dissociation rates and better ligand binding capacity than its wild-type sequence. The biological distribution experiment proves that the fusion protein provided by the present invention can rapidly and highly aggregate in the arthritis site after entering the rheumatoid arthritis mouse model, and has significant anti-adhesion / anti-inflammatory targeting inhibition effect. In the treatment of MRL / lpr lupus erythematosus mice, the fusion protein can significantly improve the survival rate of mice. Symptoms such as necrosis were significantly improved.

The invention discloses a complement receptor 2 variant, a fusion protein of the complement receptor 2 variant and a complement inhibitor and application of the fusion protein in preparing a medicament for treating autoimmune diseases. The complement receptor 2 variant is a molecular modified body obtained after computer modeling and amino acid replacement, has higher ligand binding and dissociation rate and better ligand binding force than a wild sequence of the complement receptor 2 variant. The biological distribution experiment proves that the fusion protein provided by the invention can rapidly and highly aggregate at an arthritis part after entering a rheumatoid arthritis mouse model, and has a remarkable anti-adhesion / anti-inflammation targeted inhibition effect. In the treatment ofMRL / lpr lupus erythematosus mice, the fusion protein can obviously improve the survival rate of the mice, and symptoms such as proteinuria, glomerular integral, interstitial inflammation, vasculitis,crescent / necrosis and the like of the mice in the treatment group are obviously improved.

A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).

The invention belongs to the field of Chinese medicine, relates to Prunella vulgaris polysaccharide, and a preparation method and purpose thereof in preparing anticomplement medicines. The Prunella vulgaris polysaccharide including uniform polysaccharide PW-PS1 and PW-PS2 is prepared from a dry fruit aqueous extract of a labiatae plant Prunella vulgaris Linn. Through in vitro tests, the uniform polysaccharide is proved to have strong anticomplement activity and inhibition effects on classical pathway and alternative pathway of a complement system; besides, the polysaccharide does not have the anticoagulant effect influencing in vivo activity and can be used for the preparation of complement inhibition medicaments. The PW-PS1 effects on C1q, C3 and C9 components of the complement system, and the PW-PS2 effects on the C1q, C2, C3, C5 and C9 components of the complement system.

The invention discloses acylated flavonoid glycoside compounds shown as a formula I and application thereof in preparation of complement inhibitor medicines. Acylated flavonoid glycosides extracted and separated from cudweed herb are proved to inhibit hemolysis caused by activation of a complement system in a classical pathway through in vitro experiments, and have complement inhibition effect; the activity of each monomericcompound is higher than that of a total extract of cudweed herb; and the acylated flavonoid glycoside compounds are good complement inhibitors and have low effective concentration, can serve as active ingredients to prepare novel complement inhibitor medicines for treating various diseases caused by abnormal activation of complements, are low in toxicity, safe in administration and rich in raw material sources and have great clinical application value. The structure of the formula I is shown as the specifications, wherein R1 and R2 are same or different, and respectively H, OH or OCH3; and R3 and R4 are respectively H or groups shown in the specifications.